Typhoid Fever News - LARVOL Sigma

Typhoid Fever

Welcome, Profile Billing Logout

0 Mechanisms of Action

|||||||||| Trial completion: Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) (clinicaltrials.gov) - Oct 27, 2016
P=N/A, N=1927, Completed, Sponsor: University Hospital, Geneva
Active, not recruiting --> Completed

||||||||||  Gatiflox (gatifloxacin) / Orient Europharma
Trial completion, Head-to-Head:  Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever (clinicaltrials.gov) -  Oct 4, 2016
P4, N=300, Completed,  Sponsor: Oxford University Clinical Research Unit, Vietnam
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Enrollment closed: Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=1927, Active, not recruiting, Sponsor: University Hospital, Geneva
Active, not recruiting --> Completed Recruiting --> Active, not recruiting

||||||||||  Gatiflox (gatifloxacin) / Orient Europharma
Enrollment closed, Head-to-Head:  Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever (clinicaltrials.gov) -  Jul 16, 2014
P4, N=300, Active, not recruiting,  Sponsor: Oxford University Clinical Research Unit, Vietnam
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting

|||||||||| Trial primary completion date: Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) (clinicaltrials.gov) - May 12, 2014
P=N/A, N=2170, Recruiting, Sponsor: University Hospital, Geneva
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2014 --> Dec 2014

|||||||||| Trial completion date: Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) (clinicaltrials.gov) - May 12, 2014
P=N/A, N=2170, Recruiting, Sponsor: University Hospital, Geneva
Trial primary completion date: Feb 2014 --> Dec 2014 Trial completion date: May 2014 --> Dec 2014

||||||||||  Havrix (hepatitis A vaccine, inactivated) / GSK
Trial completion:  Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood (clinicaltrials.gov) -  Feb 22, 2014
P4, N=27231, Completed,  Sponsor: International Vaccine Institute
Trial completion date: May 2014 --> Dec 2014 No longer recruiting --> Completed

||||||||||  Havrix (hepatitis A vaccine, inactivated) / GSK
Trial completion:  Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever (clinicaltrials.gov) -  Feb 22, 2014
P4, N=37673, Completed,  Sponsor: International Vaccine Institute
No longer recruiting --> Completed No longer recruiting --> Completed

||||||||||  Typhim Vi (typhoid polysaccharide vaccine) / Sanofi
Trial completion:  Exploratory Study on the Mood and Cytokine Levels in Female Healthy Participants and Major Depressive Disorder Patients (clinicaltrials.gov) -  Dec 5, 2013
P0, N=40, Completed,  Sponsor: Janssen Pharmaceutica N.V., Belgium
No longer recruiting --> Completed Recruiting --> Completed

|||||||||| Enrollment open: Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) (clinicaltrials.gov) - Jan 21, 2013
P=N/A, N=2170, Recruiting, Sponsor: University Hospital, Geneva
Recruiting --> Completed Not yet recruiting --> Recruiting

||||||||||  Typhim Vi (typhoid polysaccharide vaccine) / Sanofi
Trial completion:  Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects (clinicaltrials.gov) -  Jan 21, 2013
P3, N=200, Completed,  Sponsor: Sanofi Pasteur, a Sanofi Company
Not yet recruiting --> Recruiting Recruiting --> Completed

||||||||||  PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Trial completion:  Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants (clinicaltrials.gov) -  Sep 18, 2012
P2, N=120, Completed,  Sponsor: Novartis
Recruiting --> Completed Active, not recruiting --> Completed

||||||||||  PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Trial completion:  Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants (clinicaltrials.gov) -  Sep 18, 2012
P2, N=200, Completed,  Sponsor: Novartis
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Typhim Vi (typhoid polysaccharide vaccine) / Sanofi
Trial completion:  A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults (clinicaltrials.gov) -  Aug 28, 2012
P3, N=552, Completed,  Sponsor: Novartis
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Typhim Vi (typhoid polysaccharide vaccine) / Sanofi
New P3 trial:  Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects (clinicaltrials.gov) -  May 29, 2012
P3, N=200, Completed,  Sponsor: Sanofi Pasteur, a Sanofi Company

|||||||||| Trial completion: Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults (clinicaltrials.gov) - Jan 8, 2012
P2, N=51, Completed, Sponsor: Novartis
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Enrollment change:  Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants (clinicaltrials.gov) -  Dec 8, 2011
P2, N=120, Completed,  Sponsor: Novartis
Active, not recruiting --> Completed N=80 --> 120

||||||||||  PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Enrollment change:  Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants (clinicaltrials.gov) -  Nov 27, 2011
P2, N=200, Completed,  Sponsor: Novartis
N=80 --> 120 N=320 --> 200

||||||||||  Typhim Vi (typhoid polysaccharide vaccine) / Sanofi
New P3 trial:  A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults (clinicaltrials.gov) -  Nov 6, 2011
P3, N=552, Completed,  Sponsor: Novartis

||||||||||  PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
New P2 trial:  Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants (clinicaltrials.gov) -  Sep 18, 2011
P2, N=120, Completed,  Sponsor: Novartis

||||||||||  Gatiflox (gatifloxacin) / Orient Europharma
Enrollment open, Head-to-Head:  Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever (clinicaltrials.gov) -  Sep 18, 2011
P4, N=300, Recruiting,  Sponsor: Oxford University Clinical Research Unit, Vietnam
N=320 --> 200 Not yet recruiting --> Recruiting

|||||||||| New P2 trial: Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults (clinicaltrials.gov) - Sep 18, 2011
P2, N=51, Completed, Sponsor: Novartis

||||||||||  Gatiflox (gatifloxacin) / Orient Europharma
New P4 trial, Head-to-Head:  Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever (clinicaltrials.gov) -  Aug 21, 2011
P4, N=300, Recruiting,  Sponsor: Oxford University Clinical Research Unit, Vietnam